Long-COVID
Conditions
Interventions
Lactoferrin 4 x 300 mg capsules (total 1200 mg/day) (Bonusan) versus identical
placebo capsules
given daily during 6 weeks.
Sponsors
Longziekten
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Subjects aged 18-70 years with proven COVID-19 (positive COVID-19 RT-PCR- or antibody test) - Persistent or newly developed long COVID symptoms at least 12 weeks post-primary SARS-CoV-2 infection - Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9 months
Exclusion criteria
Exclusion criteria: - Patients admitted to the ICU (COVID-19-related) - COVID-19-related cardiac or pulmonary tissue damage - Acute infection or current systemic immunological disorders - Oral and/or inhaled use of corticosteroids or use of other immune-modulatory medication - Current psychiatric disorders - Communication difficulties - Pregnant or lactating women - Age >70 years - Patients with milk allergy or a known or suspected allergy or any contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can be used by individuals with lactose intolerance)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: Fatigue symptoms (measured with FAS) within 6 weeks and 3 months after initiation of intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: Cognitive function (CFQ), Anxiety and depression (HADS), Inflammatory parameters in blood (e.g. IL-6, hsCRP) and muscle strength (Handgrip strength and 30sec Sit-to-Stand test). | — |
Countries
Netherlands
Outcome results
None listed